2,404 results match your criteria Prescrire International [Journal]


Canadian status of "drugs to avoid" in 2017: a descriptive analysis.

Authors:
Joel Lexchin

CMAJ Open 2018 Jul-Sep;6(3):E430-E435. Epub 2018 Sep 28.

School of Health Policy and Management, York University; University Health Network; Faculty of Medicine, University of Toronto, Toronto, Ont.

Background: The independent French drug bulletin, (henceforth ), annually releases a list of drugs to avoid. The aim of this analysis was to review the status of the 2017 list of drugs in Canada to determine whether they had been approved for marketing, their therapeutic status and whether they have been recommended for listing on public drug plans.

Methods: This descriptive analysis reviewed a list of drugs compiled by . Read More

View Article
September 2018

Health Canada's use of expedited review pathways and therapeutic innovation, 1995-2016: cross-sectional analysis.

Authors:
Joel Lexchin

BMJ Open 2018 Aug 30;8(8):e023605. Epub 2018 Aug 30.

School of Health Policy and Management, York University, Toronto, Ontario, Canada.

Objectives: This study examines the use of expedited approval pathways by Health Canada over the period 1995 to 2016 inclusive and the relationship between the use of these pathways and the therapeutic gain offered by new products.

Design: Cross-sectional study.

Data Sources: Therapeutic Products Directorate, Biologics and Genetic Therapies Directorate, Notice of Compliance database, Notice of Compliance with conditions web site, Patented Medicine Prices Review Board, La revue Prescrire, WHO Anatomical Therapeutic Chemical classification system. Read More

View Article
August 2018
7 Reads

Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden.

Value Health 2018 07 21;21(7):809-821. Epub 2018 Mar 21.

Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, USA. Electronic address:

Objectives: First, to quantify the median time from European Union (EU)-wide approval to first use (launch) for a sample of cancer medicines and number of launches in Belgium, Estonia, Scotland, and Sweden as of June 2015. Second, to assess whether longer times to launch or lack of launches affected medicines with high or low expected additional clinical benefit. Third, to identify possible determinants of the probability of a cancer medicine to be launched. Read More

View Article
July 2018
3 Reads

Health sciences libraries' subscriptions to journals: expectations of general practice departments and collection-based analysis.

J Med Libr Assoc 2018 Apr 1;106(2):235-243. Epub 2018 Apr 1.

Faculté de Médecine, Département de Médecine Générale, Université de Nantes, France.

Objective: The aims of this study were to (i) assess the expectations of general practice departments regarding health sciences libraries' subscriptions to journals and (ii) describe the current general practice journal collections of health sciences libraries.

Methods: A cross-sectional survey was distributed electronically to the thirty-five university general practice departments in France. General practice departments were asked to list ten journals to which they expected access via the subscriptions of their health sciences libraries. Read More

View Article
April 2018
3 Reads

An overview of the cutaneous porphyrias.

Authors:
Robert Dawe

F1000Res 2017 30;6:1906. Epub 2017 Oct 30.

Scottish Cutaneous Porphyria Service, Scottish Photodiagnostic Unit, Department of Dermatology, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK.

This is an overview of the cutaneous porphyrias. It is a narrative review based on the published literature and my personal experience; it is not based on a formal systematic search of the literature. The cutaneous porphyrias are a diverse group of conditions due to inherited or acquired enzyme defects in the porphyrin-haem biosynthetic pathway. Read More

View Article
October 2017
14 Reads

Provincial Comparison of Pharmacist Prescribing in Canada Using Alberta's Model as the Reference Point.

Can J Hosp Pharm 2017 Sep-Oct;70(5):349-357. Epub 2017 Oct 31.

, BSP, PharmD, is with the Division of Cardiology, University of Alberta, Edmonton, Alberta.

Background: In the past decade, pharmacist practice has evolved tremendously in Canada, but the scope of practice varies substantially from one province to another.

Objective: To describe pharmacists' scopes of practice relevant to prescribing within various jurisdictions of Canada, using the prescribing model in Alberta (authors' province) as the reference point.

Methods: This cross-sectional survey consisted of clinical scenarios for emergency prescribing, adapting or renewing a prescription, and initial-access prescribing for a chronic disease. Read More

View Article
October 2017
2 Reads

Evaluating the effects of Quebec's private-public drug insurance system.

CMAJ 2017 10;189(40):E1259-E1263

School of Population and Public Health (Morgan), University of British Columbia, Vancouver, BC; School of Public Policy and Administration (Gagnon), Carleton University, Ottawa, Ont.; Karl Polanyi Institute of Political Economy (Charbonneau), Concordia University; Family and Emergency Medicine Department (Vadeboncoeur), Montreal University, Montréal, Que.

View Article
October 2017
2 Reads

The relation between promotional spending on drugs and their therapeutic gain: a cohort analysis.

Authors:
Joel Lexchin

CMAJ Open 2017 Sep;5(3):E724-E728

Affiliations: School of Health Policy and Management (Lexchin), York University and University Health Network (Lexchin), Toronto, Ont.

Background: Whether drug promotion helps or hinders appropriate prescribing by physicians is debated. This study examines the most heavily promoted drugs and the therapeutic value of those drugs to help determine whether doctors should be using promotional material to inform themselves about drugs.

Methods: Lists were constructed of the 50 most heavily promoted drugs (amount of money spent on journal advertisements and visits by sales representatives) and the 50 top-selling drugs (by dollar value) for 2013, 2014 and 2015. Read More

View Article
September 2017
5 Reads

The role and impact of cost-sharing mechanisms for prescription drug coverage.

CMAJ 2017 05;189(19):E680-E681

School of Public Policy and Administration, Carleton University, Ottawa, Ont.

View Article

[The essentiality and rationality of the Brazilian national listing of essential medicines].

Cien Saude Colet 2017 Mar;22(3):975-986

Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade de Sorocaba. Rodovia Raposo Tavares Km 92,5. 18023-000 Sorocaba SP Brasil.

One strategy to implement the rational use of medicines is the adoption of an 'essential medicines list'. The objective of this study was to analyze the list of medicines contained in the Brazilian National Relation of Essential Medicines (Rename, 2013) in terms of essentiality and rationality. Essentiality was determined by comparing this list to the 18th Essential Medicines List (EML) published by the World Health Organization (WHO). Read More

View Article
March 2017
3 Reads

Les médecins de famille devraient-ils prescrire des médicaments contre l'obésité? NON.

Authors:
Elizabeth Shaw

Can Fam Physician 2017 Feb;63(2):108-109

Médecin de famille et professeure de médecine familiale à l'Université McMaster à Hamilton, en Ontario.

View Article
February 2017
2 Reads

How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study.

Authors:
Joel Lexchin

Healthc Policy 2016 11;12(2):65-75

Professor Emeritus, School of Health Policy and Management, York University, Emergency Physician, University Health Network, Associate Professor, Department of Family and Community Medicine, University of Toronto, Toronto, ON.

Introduction: First-in-class drugs use a unique mechanism of action. This study assessed the therapeutic innovativeness and safety of these drugs approved by Health Canada from 1997-2012.

Methods: A list of new drugs was compiled and a database from the Food and Drug Administration was used to determine first-in-class status. Read More

View Article
November 2016
1 Read

Determinants of utilisation differences for cancer medicines in Belgium, Scotland and Sweden.

Eur J Health Econ 2017 Dec 9;18(9):1095-1105. Epub 2016 Dec 9.

Department of Social Policy, London School of Economics and Political Science, London, UK.

Background: Little comparative evidence is available on utilisation of cancer medicines in different countries and its determinants. The aim of this study was to develop a statistical model to test the correlation between utilisation and possible determinants in selected European countries.

Methods: A sample of 31 medicines for cancer treatment that obtained EU-wide marketing authorisation between 2000 and 2012 was selected. Read More

View Article
December 2017
8 Reads

Andrew Herxheimer: medicine for the people.

Authors:

Prescrire Int 2016 Jun;25(172):164

View Article
June 2016
8 Reads

Drug packaging in 2015: risky industry choices and lax regulation.

Authors:

Prescrire Int 2016 Jun;25(172):159-63

Prescrire examined the packaging quality of 240 drugs in 2015. No new advances were identified, but drug packaging continues to expose patients to a variety of dangers. Some past advances persist: for example, INNs are often more legible, and recent patient leaflets tend to be clearer and more informative. Read More

View Article
June 2016
9 Reads

Pulmonary embolism and thrombolysis.

Authors:

Prescrire Int 2016 Jun;25(172):158

A meta-analysis of studies including about 2000 patients with pulmonary embolism suggests that thrombolysis slightly reduces overall mortality at one month in patients under 65 but increases the number of major bleeding events, including intracranial haemorrhage. Read More

View Article
June 2016
8 Reads

Pneumococcal conjugate vaccine: do not routinely vaccinate adults aged 65 years and older.

Authors:

Prescrire Int 2016 Jun;25(172):157-8

A randomised placebo-controlled trial of 13-valent pneumococcal conjugate vaccine was conducted in about 84 500 adults aged 65 years and older, with no particular risk factors. Four years on average after vaccination, there was no reduction in either mortality or the overall incidence of community-acquired pneumonia. It was necessary to vaccinate about 1000 individuals in order to prevent one case of vaccine-type pneumococcal pneumonia during the 4-year follow-up period. Read More

View Article
June 2016
20 Reads

Bisphosphonates: osteonecrosis of the external auditory canal.

Authors:

Prescrire Int 2016 Jun;25(172):154

View Article
June 2016
23 Reads

Sofosbuvir: bradycardia.

Authors:

Prescrire Int 2016 Jun;25(172):154

View Article
June 2016
7 Reads

Azithromycin: pyloric stenosis in neonates.

Authors:

Prescrire Int 2016 Jun;25(172):154

View Article
June 2016
8 Reads

Sympathomimetic decongestants during pregnancy: risks for the unborn child.

Authors:

Prescrire Int 2016 Jun;25(172):153

In addition to the risk of cardiovascular events and neurological disorders, sympathomimetic decongestants have teratogenic potential, albeit weak, when taken during the first trimester of pregnancy, probably through disruption of the vascular system of the embryo and the pregnant woman. In the second and third trimesters of pregnancy, the fetus is exposed to the same adverse effects as the mother. Read More

View Article
June 2016
19 Reads

COMMON STEM. -astine.

Authors:

Prescrire Int 2016 Jun;25(172):152

View Article
June 2016
5 Reads

Efavirenz in children. Minimal evaluation.

Authors:

Prescrire Int 2016 Jun;25(172):152

View Article
June 2016
14 Reads

Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis.

Authors:

Prescrire Int 2016 Jun;25(172):149-51

When PUVA therapy and immunosuppressants such as methotrexate are ineffective, TNF alpha antagonists are an option for patients with severe plaque psoriasis, in the absence of a better alternative. This is also the case for patients with psoriatic arthritis after failure of a "disease-modifying" antirheumatic drug. Apremilast, an oral immunosuppressant that inhibits phosphodiesterase type 4, has been authorised in the European Union for use in these settings. Read More

View Article
June 2016
12 Reads

Empagliflozin (Jardiance). Type 2 diabetes: no rush to use this drug.

Authors:

Prescrire Int 2016 Jun;25(172):145-8

* In early 2016, metformin monotherapy remains the treatment of choice for most patients with type 2 diabetes. There are several alternatives for patients in whom metformin is poorly tolerated or ineffective. However, dapagliflozin and canagiflozin have an unfavourable harm-benefit balance and should not be used to enhance the action of metformin. Read More

View Article
June 2016
8 Reads

The drug pricing racket.

Authors:

Prescrire Int 2016 Jun;25(172):144

View Article
June 2016
38 Reads

TB, AIDS: major progress

Authors:

Prescrire Int 2016 Jul;25(173):172

View Article
July 2016
1 Read

Olmesartan: sprue-like enteropathy.

Authors:

Prescrire Int 2016 May;25(171):130-1

A cohort study conducted in 2014, using data from France's mandatory health insurance system, has shown a 10-fold increased risk of hospitalisation for enteropathy with olmesartan in comparison with other ARBs (sartans) or ACE inhibitors. The increased incidence of enteropathy with olmesartan compared with other ARBs or ACE inhibitors is well documented. The French drug regulatory agency, ANSM, informed healthcare professionals of these risks in 2014. Read More

View Article
May 2016
18 Reads

Ondansetron and pregnancy: possible congenital heart defects.

Authors:

Prescrire Int 2016 May;25(171):129-30

Two cohort studies, including more than 2500 pregnant women exposed to ondansetron in early pregnancy, have raised concerns over an increased risk of congenital heart defects. Read More

View Article
May 2016
11 Reads

Drug-induced hair loss.

Authors:

Prescrire Int 2016 May;25(171):127-9

Hair loss can have major psychological consequences. It can be due to a wide variety of causes, including hormonal disorders, dietary factors, infections, inflammation, trauma, emotional factors, and cancer. Drugs can also induce hair loss, by interacting with the hair growth cycle. Read More

View Article
May 2016
12 Reads

COMMON STEM--setron.

Authors:

Prescrire Int 2016 May;25(171):125

View Article
May 2016
17 Reads

Intense pharma lobbying in the EU.

Authors:

Prescrire Int 2016 May;25(171):116

View Article
May 2016
9 Reads

Mirabegron: hypertension, stroke.

Authors:

Prescrire Int 2016 Apr;25(170):100

View Article
April 2016
10 Reads

Gliptins: disabling joint pain.

Authors:

Prescrire Int 2016 Apr;25(170):100

View Article
April 2016
7 Reads

SSRI antidepressants: extrapyramidal reactions.

Authors:

Prescrire Int 2016 Apr;25(170):100

View Article
April 2016
11 Reads

Crizotinib: heart failure.

Authors:

Prescrire Int 2016 Apr;25(170):99

View Article
April 2016
7 Reads

Isotretinoin: anal fissure.

Authors:

Prescrire Int 2016 Mar;25(169):72

View Article
March 2016
8 Reads

BCG Vaccine SSI: numerous errors.

Authors:

Prescrire Int 2016 Mar;25(169):72

View Article
March 2016
9 Reads

Tendon disorders with ofloxacin ear drops.

Authors:

Prescrire Int 2016 Mar;25(169):72

View Article
March 2016
17 Reads

Racecadotril + ACE inhibitors: angioedema.

Authors:

Prescrire Int 2016 Mar;25(169):71

View Article
March 2016
33 Reads

Noscapine: angioedema.

Authors:

Prescrire Int 2016 Mar;25(169):71

View Article
March 2016
5 Reads

Optic neuritis with TNF alpha antagonists.

Authors:

Prescrire Int 2016 Mar;25(169):70

View Article
March 2016
12 Reads

Towards better patient care: drugs to avoid in 2016.

Authors:

Prescrire Int 2016 Apr;25(170):105-11

To help healthcare professionals and patients choose high-quality treatments that minimize the risk of adverse effects, in early 2016 we updated our list of drugs to avoid. Prescrire's assessments of the harm-benefit balance of new drugs and indications are based on a rigorous procedure that includes a systematic and reproducible literature search, identification of patient-relevant outcomes, prioritisation of the supporting data based on the strength of evidence, comparison with standard treatments, and an analysis of both known and potential adverse effects. This 2016 review of medications examined by Prescrire over a six-year period, from 2010 to 2015, identified 74 drugs that are more harmful than beneficial in all the indications for which they have been authorised in France. Read More

View Article
April 2016
12 Reads

Drugs to avoid in pregnant women with allergies.

Authors:

Prescrire Int 2016 Apr;25(170):103

View Article
April 2016
4 Reads

Allergic rhinitis during pregnancy.

Authors:

Prescrire Int 2016 Apr;25(170):101-2, 104

During pregnancy, the first-choice drugs for allergic rhinitis are nasal or oral "non-sedating" antihistamines without antimuscarinic activity, in particular cetirizine, or loratadine after the first trimester. Read More

View Article
April 2016
45 Reads